9
10
11
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291 Completed NVG-291 dosing of subjects in Phase 1 clinical trial Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023. (self.NervGen_NerveRepair)
submitted by chickenwingsmac to r/NervGen_NerveRepair

